Solid Tumors

Mesothelin-Expressing Cancers Colorectal Cancer Melanoma Head and Neck Cancer Lung Cancer Pancreatic Cancer

Phase 1 TCER IMA401 Shows Early Safety and Tumor Responses in Solid Cancers

Data presented May 31 show manageable immune‑activation side effects and encouraging responses that justify planned combination studies and larger trials.

3 ARTICLES

3mo ago

Solid Tumors

Phase 1 TCER IMA401 Shows Early Safety and Tumor Responses in Solid Cancers

First-in-Human SynKIR-110 Shows Safe Profile and Early Activity in Solid Tumors